AcouSort will launch AcouWash 2 at international conference
AcouSort will launch the new version of its cell washing and separation system AcouWash during µTAS, an international conference attended by many industry professionals and key opinion leaders within Life Science held in October. The new version of the system features improved performance and a more user-friendly design.
– We are very excited to present AcouWash 2 atµTAS, wich is a great platform for introducing it to the market. The conference is frequently visited by life science companies looking for new technologies that can enable additional features in their next generation instruments. The updated AcouWash system will be a great way of allowing these companies to evaluate our acoustic separation technology. It enables them to use the system to develop assays that later can be incorporated in their clinical systems using our technology and OEM components. In the long-term, this can potentially lead to more OEM deals, says AcouSort’s CEO Torsten Freltoft.
AcouWash is a benchtop research instrument that uses acoustic separation to wash or separate cells in for example a blood sample. Common applications include separation of specific, sensitive white blood cells and generation of very pure plasma from whole blood samples. The new version features higher throughput with improved temperature- and flow control. µTAS is an international conference on Miniaturized Systems for Chemistry and Life Sciences, where AcouSort this year will be a virtual exhibitor.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.